EGRIFTA

This brand name is authorized in Canada, United States

Active ingredients

The drug EGRIFTA contains one active pharmaceutical ingredient (API):

1 Tesamorelin UNII LGW5H38VE3 - TESAMORELIN ACETATE

Tesamorelin is indicated for the treatment of excess visceral adipose tissue (VAT) in treatment-experienced adult HIV-infected patients with lipodystrophy. In vitro, tesamorelin binds and stimulates human GRF receptors with similar potency as the endogenous GRF, and subsequently increases IGF-1 and IGFBP-3 levels. Read about Tesamorelin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
EGRIFTA Powder for solution fot injection	Health Products and Food Branch (CA)	MPI, CA: SPM
EGRIFTA SV Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
H01AC06	Tesamorelin	H Systemic hormonal preparations, excl. Sex hormones and insulins → H01 Pituitary and hypothalamic hormones and analogues → H01A Anterior pituitary lobe hormones and analogues → H01AC Somatropin and somatropin agonists
Discover more medicines within H01AC06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02438712
Country: US	FDA, National Drug Code	Identifier(s): 62064-241